09. 10(Thu)
09. 10(Thu)
13:00~14:30 Room 2
Inflammation in ASCVD: From LDL Lowering to Immune Modulation
-
LDL versus inflammation: what remains after aggressive lipid lowering?
Oh-sung Kwon The Catholic University of Korea, Republic of Korea 13:00~13:18 -
Emerging anti-inflammatory therapies in ASCVD: canakinumab, NLRP3 inhibitors, and beyond
Sung-A Bae Yonsei University, Republic of Korea 13:18~13:36 -
Colchicine for secondary prevention in ASCVD
Dae Young Cheon Hallym University, Republic of Korea 13:36~13:54 -
Immune mechanisms of residual cardiovascular risk: from oxidation-specific epitopes to therapeutic targets
Christoph J. Binder Medical University of Vienna, Austria 13:54~14:12 - Panel Discussion 14:12~14:30
09. 10(Thu)
14:30~16:00 Room 2
FH/Severe Dyslipidemia: Optimizing FH Management
Chairperson(s) : Hayato Tada (Kanazawa University, Japan)
-
Refined risk assessment in FH
Sayaka Funabashi Kyorin University, Japan 14:30~14:48 - Q&A 14:48~14:52
-
Cause of death in FH
Chan Joo Lee Yonsei University, Republic of Korea 14:52~15:10 - Q&A 15:10~15:14
-
Experience on new drugs for FH: including lomitapide & evinacumab
Hayato Tada Kanazawa University, Japan 15:14~15:32 - Q&A 15:32~15:36
-
Genome editing for precision medicine
HyongBum Kim Yonsei University, Republic of Korea 15:36~15:54 - Q&A 15:54~15:58
